<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardio</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиология</journal-title><trans-title-group xml:lang="en"><trans-title>Kardiologiia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0022-9040</issn><issn pub-type="epub">2412-5660</issn><publisher><publisher-name>Kardiomag</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18087/cardio.2022.8.n1706</article-id><article-id custom-type="elpub" pub-id-type="custom">cardio-1706</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group></article-categories><title-group><article-title>Диастолическая дисфункция и сердечная недостаточность с сохраненной фракцией выброса левого желудочка у больных резистентной артериальной гипертензией в сочетании с сахарным диабетом 2 типа</article-title><trans-title-group xml:lang="en"><trans-title>Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction In Patients With Resistant Hypertension and Type 2 Diabetes Mellitus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3577-1895</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Манукян</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Manukyan</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант, младший научный сотрудник  отделения артериальных гипертоний</p></bio><bio xml:lang="en"><p>Post-Graduate Student, Junior Research Scientist, Department of Hypertension</p></bio><email xlink:type="simple">manukyan.muscheg@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5638-3034</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фальковская</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Falkovskaya</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., старший научный сотрудник, и.о. руководителя отделения артериальных гипертоний</p></bio><bio xml:lang="en"><p>MD, Ph.D., Senior Research Scientist, Acting Head of the Department of Hypertension</p></bio><email xlink:type="simple">alla@cardio.tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6995-9875</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зюбанова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zyubanova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., младший научный сотрудник отделения артериальных гипертоний</p></bio><bio xml:lang="en"><p>MD, Ph.D., Junior Researcher of the Department of Hypertension</p></bio><email xlink:type="simple">zyubanovaiv@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4066-869X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Личикаки</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lichikaki</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., научный сотрудник отделения артериальных гипертоний</p></bio><bio xml:lang="en"><p>MD, Ph.D., Researcher of the Department of Hypertension</p></bio><email xlink:type="simple">manankovalera@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9857-4368</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цой</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsoi</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>научный сотрудник отделения артериальных гипертоний</p></bio><bio xml:lang="en"><p>MD, Researcher of the Department of Hypertension</p></bio><email xlink:type="simple">haksen_sgmu@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8573-5695</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рябова</surname><given-names>Т. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryabova</surname><given-names>T. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., старший научный сотрудник отделения ультразвуковой и функциональной диагностики</p></bio><bio xml:lang="en"><p>MD, Ph.D., Senior Researcher of the Department of Laboratory and Functional Diagnostics</p><p> </p><p> </p></bio><email xlink:type="simple">rtrtom@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3147-3025</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гусакова</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Gusakova</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.ф.н., научный сотрудник клинико-диагностической лаборатории</p></bio><bio xml:lang="en"><p>MD, Ph.D., Researcher of the Department of Laboratory and Functional Diagnostics</p></bio><email xlink:type="simple">mag_a@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9645-6720</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суслова</surname><given-names>Т. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Suslova</surname><given-names>T. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., руководитель клинико-диагностической лаборатории</p></bio><bio xml:lang="en"><p>MD, Ph.D., Head of Department of lab diagnostic</p></bio><email xlink:type="simple">tes@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2238-4573</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мордовин</surname><given-names>В. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Mordovin</surname><given-names>V. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор,   ведущий научный сотрудник отделения артериальных гипертоний</p></bio><bio xml:lang="en"><p>MD, Ph.D., Leading Researcher of the Department of Hypertension</p></bio><email xlink:type="simple">mordovin@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр РАН, Томск</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Cardiology, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>30</day><month>08</month><year>2022</year></pub-date><volume>62</volume><issue>8</issue><fpage>11</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kardiomag, 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Kardiomag</copyright-holder><copyright-holder xml:lang="en">Kardiomag</copyright-holder><license xlink:href="https://cardio.elpub.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://cardio.elpub.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://cardio.elpub.ru/jour/article/view/1706">https://cardio.elpub.ru/jour/article/view/1706</self-uri><abstract><p>Цель    Изучить частоту развития и клинико-патофизиологические особенности диастолической дисфункции (ДД) и хронической сердечной недостаточности с сохраненной фракцией выброса (ХСНсФВ) у больных резистентной артериальной гипертензией (РАГ) в сочетании с сахарным диабетом (СД) 2‑го типа.</p><p>Материал и методы  Проведено одномоментное простое исследование, в котором приняли участие 36 больных РАГ в сочетании с СД 2‑го типа (средний возраст 61,4±6,4 года; 14 мужчин). Всем больным проводили измерение офисного и 24‑часового артериального давления (АД), эхокардиографию по стандартной методике с оценкой диастолической функции (ДФ) и желудочково-артериального сопряжения, допплерографию почечного кровотока, лабораторные тесты (глюкоза крови, гликированный гемоглобин, креатинин крови, альфа-фактор некроза опухоли – альфа-ФНО, мозговой натрийуретический пептид – МНУП, матриксные металлопротеиназы 2‑го и 9‑го типов – ММП-2, ММП-9, тканевый ингибитор матриксной металлопротеиназы-1 – ТИМП-1, суточная протеинурия и объем суточной мочи). ХСНсФВ диагностировали в соответствии с критериями Американского общества эхокардиографии и Европейского общества кардиологов 2019 г., Российскими клиническими рекомендациями по диагностике и лечению ХСН от 2017 и 2020 гг.</p><p>Результаты   ДД имелась у всех обследованных пациентов. Частота выявления ХСНсФВ, согласно Российским рекомендациям 2017 г., составила 100 %, по рекомендациям 2020 г., включающим обязательное повышение МНУП, а также по критериям Европейских рекомендаций от 2019 г. – 89 %. В 55,6 % случаев ДД соответствовала II степени (псевдонормальному типу). Согласно корреляционному анализу ухудшение ДФ было связано с увеличением пульсового АД, массы миокарда, артериального и левожелудочкового эластанса (эластичности артериальной стенки и левого желудочка), базальной гликемии и длительности СД, уровня ММП-2, протеинурии, креатинина крови и сосудистого сопротивления в почках, а также с уменьшением объема суточной мочи, снижением уровня ММП-9, ТИМП-1 и ТИМП-1 / ММП-2. Значимость взаимосвязей среднего отношения E / e’ с уровнем ночного пульсового АД, ММП-9 и объемом суточной мочи подтверждена результатами множественного линейного регрессионного анализа. Повышение жесткости миокарда и сосудистой стенки, увеличение уровня ММП-2, альфа-ФНО и снижение объема суточной мочи ассоциировались с прогрессирующим ухудшением ДФ.</p><p>Заключение     Для сочетания РАГ и СД 2‑го типа характерна крайне высокая частота развития ДД, определяющая высокую распространенность ХСНсФВ. Развитие и прогрессирование ДД у больных данной категории тесно связано с комплексом метаболических, провоспалительных и профибротических биомаркеров, повышением жесткости сосудистой стенки, выраженностью гипертрофии левого желудочка, а также со структурно-функциональными изменениями почек.</p></abstract><trans-abstract xml:lang="en"><p>Aim      To study the incidence and clinical and pathophysiological features of diastolic dysfunction (DD) and chronic heart failure with preserved ejection fraction (HFpEF) in patients with resistant arterial hypertension (RAH) associated with type 2 diabetes mellitus (DM).</p><p>Material and methods  A cross-sectional study that included 36 patients with RAH associated with type 2 DM (mean age, 61.4±6.4 years; 14 men) was performed. Measurement of office and 24-h blood pressure (BP), standard echocardiography with assessment of diastolic function (DF) and ventricular-arterial coupling, doppler ultrasound imaging of renal blood flow, and laboratory tests (blood glucose, glycated hemoglobin, blood creatinine, tumor necrosis factor α (TNF-α), brain natriuretic peptide (BNP), type 2 and type 9 matrix metalloproteinases (MMP-2 and MMP-9), tissue inhibitor of MMP 1 (TIMP-1), 24-h urine protein test, and 24-h urine volume test were performed for all patients. HFpEF was diagnosed according to criteria of the American Society of Echocardiography and the European Society of Cardiology 2019, and the Russian Clinical Guidelines on Diagnosis and Treatment of CHF 2017 and 2020.</p><p>Results All patients had DD. Incidence of HFpEF detection according to the Russian Guidelines 2017 was 100%; according to the Russian Guidelines 2020, that included a required increase in BNP, and according to the criteria of the European Guidelines 2019, this incidence was 89 %. In 55.6 % of patients, DD corresponded to grade 2 (pseudonormal type). According to the correlation analysis, the DF impairment was associated with increases in pulse BP, myocardial mass, arterial and left ventricular elastance (arterial wall and left ventricular elasticity), basal glycemia and DM duration, MMP-2 level, proteinuria, blood creatinine, renal vascular resistance, and also with decreases in 24-h urine volume, MMP-9, TIMP-1, and TIMP-1/MMP-2. Significance of the relations of mean E / e’ ratio with nighttime pulse BP, MMP-9, and 24-h urine volume were confirmed by results of multiple linear regression analysis. Increased myocardial and vascular wall stiffness, concentrations of MMP-2 and TNF-α and reduced 24-h urine volume were associated with progressive impairment of DF.</p><p>Conclusion      The combination of RAH and DM-2 is characterized by an extremely high incidence of DD that determines a great prevalence of HFpEF. The development and progression of DD in such patients are closely related with a complex of metabolic, proinflammatory and profibrotic biomarkers, increased vascular wall stiffness, pronounced left ventricular hypertrophy, and with structural and functional alterations in kidneys.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Диастолическая дисфункция</kwd><kwd>сердечная недостаточность с сохраненной фракцией выброса левого желудочка</kwd><kwd>сахарный диабет 2‑го типа</kwd><kwd>резистентная артериальная гипертензия</kwd><kwd>биомаркеры</kwd><kwd>воспаление</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Diastolic dysfunction</kwd><kwd>heart failure with preserved left ventricular ejection fraction</kwd><kwd>type 2 diabetes mellitus</kwd><kwd>resistant arterial hypertension</kwd><kwd>biomarkers</kwd><kwd>inflammation</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при финансовой поддержке РФФИ в рамках научного проекта № 20-315-90068.  Конфликт интересов не заявлен.</funding-statement><funding-statement xml:lang="en">The study was supported by the Russian Foundation for Basic Research as a part of the project #20-315-90068. No conflict of interest is reported.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kosmala W, Marwick TH. Asymptomatic Left Ventricular Diastolic Dysfunction. JACC: Cardiovascular Imaging. 2020;13(1 Pt 2):215– 27. DOI: 10.1016/j.jcmg.2018.10.039</mixed-citation><mixed-citation xml:lang="en">Kosmala W, Marwick TH. Asymptomatic Left Ventricular Diastolic Dysfunction: Predicting Progression to Symptomatic Heart Failure. JACC Cardiovasc Imaging.2020; 13(1Pt2):215-227. DOI:10.1016/j.jcmg.2018.10.039</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Nayor M et al. The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. JACC: Heart Failure. 2018;6(8):701–9. DOI: 10.1016/j.jchf.2018.05.018</mixed-citation><mixed-citation xml:lang="en">Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M. et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC: Heart Failure. 2018; 6(8), 701-709. DOI:10.1016/j.jchf.2018.05.018</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang W, Liu C, Ji L, Wang J, For the ATTEND investigators. Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes. The Journal of Clinical Hypertension. 2020;22(2):212–20. DOI: 10.1111/jch.13793</mixed-citation><mixed-citation xml:lang="en">Zhang W, Liu CY, Ji LN, Wang JG; ATTEND investigators. Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes. J Clin Hypertens (Greenwich). 2020; 22(2):212-220. DOI: 10.1111/jch.13793</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J-H, Chen Y, Yuen M, Zhen Z, Chan CW-S, Lam KS-L et al. Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus. Cardiovascular Diabetology. 2016;15(1):22. DOI: 10.1186/s12933-016-0333-5</mixed-citation><mixed-citation xml:lang="en">Pieske, B., Tschöpe, C., De Boer, R. A., Fraser, A. G., Anker, S. D., Donal, E. et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019; 40: 3297–3317.  DOI:10.1093/eurheartj/ehz641</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Blomstrand P, Engvall M, Festin K, Lindstrom T, Lanne T, Maret E et al. Left ventricular diastolic function, assessed by echocardiography and tissue Doppler imaging, is a strong predictor of cardiovascular events, superior to global left ventricular longitudinal strain, in patients with type 2 diabetes. European Heart Journal - Cardiovascular Imaging. 2015;16(9):1000–7. DOI: 10.1093/ehjci/jev027</mixed-citation><mixed-citation xml:lang="en">Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatmen. Kardiologiia. 2018; 58 (6S): 8–164. [Russian: Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбекова Ю.Л., Васюк Ю.А., Гарганеева А.А. и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология.2018; 58(6S):8- 164]. DOI: 10.18087/cardio.2475</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297– 317. DOI: 10.1093/eurheartj/ehz641</mixed-citation><mixed-citation xml:lang="en">Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020; 25(11):4083. [Russian: Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083:]. DOI:10.15829/1560-4071-2020-4083</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–158. [Russian: Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбекова Ю.Л., Васюк Ю.А., Гарганеева А.А. и др. Клинические рекомендации ОССН–РКО–РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158]. DOI: 10.18087/cardio.2475</mixed-citation><mixed-citation xml:lang="en">Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., 3rd, Dokainish, H., Edvardsen, T. et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography.2016; 29(4), 277–314. DOI: 10.1016/j.echo.2016.01.011</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageev F.T., Arutyunov G.P., Begrambekova Yu.L. et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311–74. [Russian: Терещенко С.Н. Галявич А.С., Ускач Т.М., Агеев Ф.Т., Арутюнов Г.П., Беграмбекова Ю.Л. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):311-74]. DOI: 10.15829/1560-4071-2020-4083</mixed-citation><mixed-citation xml:lang="en">Naqvi TZ. Diastolic function assessment incorporating new techniques in Doppler echocardiography. Rev Cardiovasc Med. 2003 Spring;4(2):81-99. PMID: 12776017</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Naqvi TZ. Diastolic function assessment incorporating new techniques in Doppler echocardiography. Reviews in Cardiovascular Medicine. 2003;4(2):81–99. PMID: 12776017</mixed-citation><mixed-citation xml:lang="en">Chen CH, Fetics B, Nevo E, Rochitte CE, Chiou KR, Ding PA et al. Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. J Am Coll Cardiol. 2001; 38(7):2028-34. DOI: 10.1016/s0735-1097(01)01651-5</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chen C-H, Fetics B, Nevo E, Rochitte CE, Chiou K-R, Ding P-A et al. Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. Journal of the American College of Cardiology. 2001;38(7):2028–34. DOI: 10.1016/S0735-1097(01)01651-5</mixed-citation><mixed-citation xml:lang="en">Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25(3):3786. [Russian:Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786]. DOI:10.15829/1560-4071-2020-3-3786</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I. et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):149–218. [Russian: Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):149-218]. DOI: 10.15829/1560-4071-2020-3-3786</mixed-citation><mixed-citation xml:lang="en">Bouthoorn, S., Valstar, G. B., Gohar, A., den Ruijter, H. M., Reitsma, H. B., Hoes, A. W. et al. The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: A systematic review and meta-analysis. Diabetes &amp; vascular disease research.2018; 15(6), 477–493. DOI: 10.1177/1479164118787415</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Bouthoorn S, Valstar GB, Gohar A, den Ruijter HM, Reitsma HB, Hoes AW et al. The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: A systematic review and meta-analysis. Diabetes and Vascular Disease Research. 2018;15(6):477–93. DOI: 10.1177/1479164118787415</mixed-citation><mixed-citation xml:lang="en">Nadruz W, Shah AM., Solomon SD. Diastolic Dysfunction and Hypertension. Surg Clin North Am.2017; 101(1): 7–17. DOI:10.1016/j.mcna.2016.08.013</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Nadruz W, Shah AM, Solomon SD. Diastolic Dysfunction and Hypertension. Medical Clinics of North America. 2017;101(1):7–17. DOI: 10.1016/j.mcna.2016.08.013</mixed-citation><mixed-citation xml:lang="en">Jin CN, Liu M, Sun JP, Fang F, Wen YN, Yu CM et al. The prevalence and prognosis of resistant hypertension in patients with heart failure. PLoS One. 2014;9(12):e114958. DOI: 10.1371/journal.pone.0114958</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Jin C-N, Liu M, Sun J-P, Fang F, Wen Y-N, Yu C-M et al. The Prevalence and Prognosis of Resistant Hypertension in Patients with Heart Failure. PLoS ONE. 2014;9(12):e114958. DOI: 10.1371/journal.pone.0114958</mixed-citation><mixed-citation xml:lang="en">Mareev Yu.V., Garganeeva A.A., Tukish O.V., Rebrova T.Yu., Anikina D.V., Mareev V.Yu. Difficulties in diagnosis of heart failure with preserved ejection fraction in clinical practice: dissonance between echocardiography, NTproBNP and H2HFPEF score. Kardiologiia. 2019;59(12S):37-45. [Russian: Мареев Ю.В., Гарганеева А.А., Тукиш О.В., Реброва Т.Ю., Аникина Д.В., Мареев В.Ю. Сложности в диагностике сердечной недостаточности с сохраненной фракцией выброса в реальной клинической практике: диссонанс между клиникой, эхокардиографическими изменениями, величиной натрийуретических пептидов и шкалой H2FPEF. Кардиология. 2019;59(12S):37-45.]. DOI:10.18087/cardio.n695</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mareev Yu.V., Garganeeva A.A., Tukish O.V., Rebrova T.Yu., Anikina D.V., Mareev V.Yu. Difficulties in diagnosis of heart failure with preserved ejection fraction in clinical practice: dissonance between echocardiography, NTproBNP and H2HFPEF score. Kardiologiia. 2020;59(12S):37–45. [Russian: Мареев Ю.В., Гарганеева А.А., Тукиш О.В., Реброва Т.Ю., Аникина Д.В., Мареев В.Ю. Сложности в диагностике сердечной недостаточности с сохраненной фракцией выброса в реальной клинической практике: диссонанс между клиникой, эхокардиографическими изменениями, величиной натрийуретических пептидов и шкалой H2FPEF. Кардиология. 2019;59(12S):37–45]. DOI: 10.18087/cardio.n695</mixed-citation><mixed-citation xml:lang="en">Anjan VY, Loftus TM, Burke MA, Akhter N, Fonarow GC, Gheorghiade M et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012; 110(6):870-6. DOI: 10.1016/j.amjcard.2012.05.014</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Anjan VY, Loftus TM, Burke MA, Akhter N, Fonarow GC, Gheorghiade M et al. Prevalence, Clinical Phenotype, and Outcomes Associated With Normal B-Type Natriuretic Peptide Levels in Heart Failure With Preserved Ejection Fraction. The American Journal of Cardiology. 2012;110(6):870–6. DOI: 10.1016/j.amjcard.2012.05.014</mixed-citation><mixed-citation xml:lang="en">Obokata M, Kane GC, Reddy YNV, Olson TP, Melenovsky V, Borlaug BA. Role of Diastolic Stress Testing in the Evaluation for Heart Failure with Preserved Ejection Fraction: A Simultaneous Invasive- Echocardiographic Study. Circulation.2017; 135(9):825–38. DOI:10.1161/CIRCULATIONAHA.116.024822</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Obokata M, Kane GC, Reddy YNV, Olson TP, Melenovsky V, Borlaug BA. Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study. Circulation. 2017;135(9):825–38. DOI: 10.1161/CIRCULATIONAHA.116.024822</mixed-citation><mixed-citation xml:lang="en">Buckley LF, Canada JM, Del Buono MG, Carbone S, Trankle CR, Billingsley H et al. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. ESC Heart Fail. 2018 Apr;5(2):372-378. DOI: 10.1002/ehf2.12235</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Buckley LF, Canada JM, Del Buono MG, Carbone S, Trankle CR, Billingsley H et al. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. ESC Heart Failure. 2018;5(2):372–8. DOI: 10.1002/ehf2.12235</mixed-citation><mixed-citation xml:lang="en">de Boer R.A., De Keulenaer G., Bauersachs J., Brutsaert D., Cleland J.G., Diez J. et al. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. Eur. J. Heart Fail. 2019; 21:272–285. DOI: 10.1002/ejhf.1406</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">de Boer RA, De Keulenaer G, Bauersachs J, Brutsaert D, Cleland JG, Diez J et al. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure. 2019;21(3):272–85. DOI: 10.1002/ejhf.1406</mixed-citation><mixed-citation xml:lang="en">Di Nicolò P, Granata A. Renal intraparenchymal resistive index: the ultrasonographic answer to many clinical questions. J Nephrol. 2019;32(4):527-538. DOI: 10.1007/s40620-018-00567-x</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tedesco MA, Natale F, Mocerino R, Tassinario G, Calabrò R. Renal resistive index and cardiovascular organ damage in a large population of hypertensive patients. Journal of Human Hypertension. 2007;21(4):291–6. DOI: 10.1038/sj.jhh.1002145</mixed-citation><mixed-citation xml:lang="en">Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113(17):2089-6. DOI:10.1161/CIRCULATIONAHA.105.573865.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Di Nicolò P, Granata A. Renal intraparenchymal resistive index: the ultrasonographic answer to many clinical questions. Journal of Nephrology. 2019;32(4):527–38. DOI: 10.1007/s40620-018-00567-x</mixed-citation><mixed-citation xml:lang="en">Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol. 2006; 26(5):1120-5. DOI: 10.1161/01.ATV.0000218496.60097.e0</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH et al. Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases: Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease. Circulation. 2006;113(17):2089–96. DOI: 10.1161/CIRCULATIONAHA.105.573865</mixed-citation><mixed-citation xml:lang="en">Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A. 2005; 102(43):15575-80. DOI: 10.1073/pnas.0506201102</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kuzuya M, Nakamura K, Sasaki T, Wu Cheng X, Itohara S, Iguchi A. Effect of MMP-2 Deficiency on Atherosclerotic Lesion Formation in ApoE-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(5):1120–5. DOI: 10.1161/01.ATV.0000218496.60097.e0</mixed-citation><mixed-citation xml:lang="en">Chavey C, Mari B, Monthouel MN, Bonnafous S, Anglard P, Van Obberghen E et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem. 2003; 278(14):11888-96. DOI: 10.1074/jbc.M209196200</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proceedings of the National Academy of Sciences. 2005;102(43):15575–80. DOI: 10.1073/pnas.0506201102</mixed-citation><mixed-citation xml:lang="en">Dunlay S. M., Weston S. A., Redfield M. M., Killian J. M., Roger V́. L. Tumor Necrosis Factor-α and Mortality in Heart Failure. Circulation. 2008; 118(6):625–631.DOI: 10.1161/CIRCULATIONAHA.107.759191</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Chavey C, Mari B, Monthouel M-N, Bonnafous S, Anglard P, Van Obberghen E et al. Matrix Metalloproteinases Are Differentially Expressed in Adipose Tissue during Obesity and Modulate Adipocyte Differentiation. Journal of Biological Chemistry. 2003;278(14):11888–96. DOI: 10.1074/jbc.M209196200</mixed-citation><mixed-citation xml:lang="en">Mocan M, Mocan Hognogi LD, Anton FP, Chiorescu RM, Goidescu CM, Stoia MA et al. Biomarkers of Inflammation in Left Ventricular Diastolic Dysfunction. Dis Markers. 2019; 2019:7583690. DOI: 10.1155/2019/7583690.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Tumor Necrosis Factor-α and Mortality in Heart Failure: A Community Study. Circulation. 2008;118(6):625–31. DOI: 10.1161/CIRCULATIONAHA.107.759191</mixed-citation><mixed-citation xml:lang="en">Dinh W, Füth R, Nickl W, Krahn T, Ellinghaus P, Scheffold T et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol. 2009; 8:58. DOI: 10.1186/1475-2840-8-58</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Mocan M, Mocan Hognogi LD, Anton FP, Chiorescu RM, Goidescu CM, Stoia MA et al. Biomarkers of Inflammation in Left Ventricular Diastolic Dysfunction. Disease Markers. 2019;2019:7583690. DOI: 10.1155/2019/7583690</mixed-citation><mixed-citation xml:lang="en">Liu JH, Chen Y, Yuen M, Zhen Z, Chan CW, Lam KS et al. Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016; 15:22. DOI: 10.1186/s12933-016-0333-5.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Dinh W, Füth R, Nickl W, Krahn T, Ellinghaus P, Scheffold T et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovascular Diabetology. 2009;8:58. DOI: 10.1186/1475-2840-8-58</mixed-citation><mixed-citation xml:lang="en">Blomstrand P, Engvall M, Festin K, Lindström T, Länne T, Maret E et al. Left ventricular diastolic function, assessed by echocardiography and tissue Doppler imaging, is a strong predictor of cardiovascular events, superior to global left ventricular longitudinal strain, in patients with type 2 diabetes. Eur Heart J Cardiovasc Imaging. 2015; 16(9):1000-7. DOI: 10.1093/ehjci/jev027.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Lüscher TF. Inflammation: the new cardiovascular risk factor. European Heart Journal. 2018;39(38):3483–7. DOI: 10.1093/eurheartj/ehy607</mixed-citation><mixed-citation xml:lang="en">Falkovskaya A.Yu., Mordovin V.F., Pekarskiy S.E., Ripp T.M., Manukyan M.A., Lichikaki V.A., Sitkova E.S., Zyubanova I.V., Gusakova A.M., Baev A.E., Ryabova T.R., Ryumshina N.I. Renal denervation as a new nephroprotective strategy in diabetic patients with resistant hypertension. The Siberian Journal of Clinical and Experimental Medicine. 2020; 35(1):80-92. [Russian: Фальковская А.Ю., Мордовин В.Ф., Пекарский С.Е., Рипп Т.М., Манукян М.А., Личикаки В.А., Ситкова Е.С., Зюбанова И.В., Гусакова А.М., Баев А.Е., Рябова Т.Р., Рюмшина Н.И. Ренальная денервация как новая стратегия нефропротекции у больных резистентной артериальной гипертонией, ассоциированной с сахарным диабетом 2-го типа. Сибирский журнал клинической и экспериментальной медицины. 2020;35(1):80-92]. DOI: 10.29001/2073-8552-2020-35-1-80-92</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">LeBaron TW, Kura B, Kalocayova B, Tribulova N, Slezak J. A New Approach for the Prevention and Treatment of Cardiovascular Disorders. Molecular Hydrogen Significantly Reduces the Effects of Oxidative Stress. Molecules. 2019;24(11):2076. DOI: 10.3390/molecules24112076</mixed-citation><mixed-citation xml:lang="en">LeBaron TW, Kura B, Kalocayova B, Tribulova N, Slezak J. A New Approach for the Prevention and Treatment of Cardiovascular Disorders. Molecular Hydrogen Significantly Reduces the Effects of Oxidative Stress. Molecules. 2019;24(11):2076. DOI: 10.3390/molecules24112076</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Cerisano G, Buonamici P, Valenti R, Sciagra R, Raspanti S, Santini A et al. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. European Heart Journal. 2014;35(3):184–91. DOI: 10.1093/eurheartj/eht420</mixed-citation><mixed-citation xml:lang="en">Cerisano G, Buonamici P, Valenti R, Sciagra R, Raspanti S, Santini A et al. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. European Heart Journal. 2014;35(3):184–91. DOI: 10.1093/eurheartj/eht420</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Falkovskaya A.Yu., Mordovin V.F., Pekarskiy S.E., Ripp T.M., Manukyan M.A., Lichikaki V.A. et al. Renal denervation as a new nephroprotective strategy in diabetic patients with resistant hypertension. The Siberian Medical Journal. 2020;35(1):80–92. [Russian: Фальковская А.Ю., Мордовин В.Ф., Пекарский С.Е., Рипп Т.М., Манукян М.А., Личикаки В.А. и др. Ренальная денервация как новая стратегия нефропротекции у больных резистентной артериальной гипертонией, ассоциированной с сахарным диабетом 2-го типа. Сибирский журнал клинической и экспериментальной медицины. 2020;35(1):80-92]. DOI: 10.29001/2073-8552-2020-35-1-80-92</mixed-citation><mixed-citation xml:lang="en">Falkovskaya A.Yu., Mordovin V.F., Pekarskiy S.E., Ripp T.M., Manukyan M.A., Lichikaki V.A. et al. Renal denervation as a new nephroprotective strategy in diabetic patients with resistant hypertension. The Siberian Medical Journal. 2020;35(1):80–92. [Russian: Фальковская А.Ю., Мордовин В.Ф., Пекарский С.Е., Рипп Т.М., Манукян М.А., Личикаки В.А. и др. Ренальная денервация как новая стратегия нефропротекции у больных резистентной артериальной гипертонией, ассоциированной с сахарным диабетом 2-го типа. Сибирский журнал клинической и экспериментальной медицины. 2020;35(1):80-92]. DOI: 10.29001/2073-8552-2020-35-1-80-92</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
